South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.
This approval came two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) issued a positive opinion in February.
South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and development unit, have secured a bid to supply its biosimilar Hadlima (adalimumab-bwwd), a treatment for autoimmune diseases, to the US Department of Vetera
Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official designation from the US Food and Drug Administration (FDA) as interchangeable with the original medicine. Samsung Bioepis is thus South Korea’s fi
Samsung Bioepis headquarters Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partnership agreement with Swiss pharmaceutical company Sandoz for sales of autoimmune disease treatment Stelara (act
Researcher at Samsung Bioepis' laboratory (Courtesy of Samsung) Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business division of Nasdaq-listed Biogen Inc. at less than 1 trillion won ($775.3 million),